These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1366 related items for PubMed ID: 31126015

  • 1. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA, Veereman G, de Ridder L.
    Int J Mol Sci; 2019 May 23; 20(10):. PubMed ID: 31126015
    [Abstract] [Full Text] [Related]

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 3. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV, Sharma R, Afzal NM, Xu W, Walsh S, Stempak JM, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS.
    Dig Dis Sci; 2018 Sep 14; 63(9):2430-2438. PubMed ID: 29736839
    [Abstract] [Full Text] [Related]

  • 4. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
    Cheon JH.
    J Gastroenterol Hepatol; 2017 Apr 14; 32(4):769-777. PubMed ID: 27723166
    [Abstract] [Full Text] [Related]

  • 5. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov 14; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 6. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
    Üsküdar Cansu D, Üsküdar Teke H, Temel T, Ertürk A, Kahraman O, Korkmaz C.
    J Natl Med Assoc; 2019 Jun 14; 111(3):262-269. PubMed ID: 30389147
    [Abstract] [Full Text] [Related]

  • 7. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM.
    Pediatr Dermatol; 2017 May 14; 34(3):253-260. PubMed ID: 28211161
    [Abstract] [Full Text] [Related]

  • 8. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.
    Dig Dis Sci; 2018 Jun 14; 63(6):1583-1591. PubMed ID: 29564674
    [Abstract] [Full Text] [Related]

  • 9. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review.
    Martín-García P, Alonso-Arroyo A, Catalá-López F.
    Med Clin (Barc); 2023 Jun 09; 160(11):501-516. PubMed ID: 36967304
    [Abstract] [Full Text] [Related]

  • 10. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar 09; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 11. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N.
    Aliment Pharmacol Ther; 2019 Mar 09; 49(6):664-680. PubMed ID: 30735257
    [Abstract] [Full Text] [Related]

  • 12. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM, Lee HH, Lee BI, Lee KM, Eun SH, Cho ML, Kim JS, Park JM, Cho YS, Lee IS, Kim SW, Choi H, Choi MG.
    Aliment Pharmacol Ther; 2018 Jul 09; 48(2):196-205. PubMed ID: 29869804
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R, Curci D, Lucafò M, Decorti G, Stocco G.
    Expert Opin Drug Metab Toxicol; 2019 Jul 09; 15(7):527-539. PubMed ID: 31177858
    [Abstract] [Full Text] [Related]

  • 14. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 09; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, Hagag RS.
    Inflammopharmacology; 2024 Oct 09; 32(5):3259-3269. PubMed ID: 38985232
    [Abstract] [Full Text] [Related]

  • 16. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S, Ahuja V, Makharia GK.
    Expert Rev Clin Pharmacol; 2016 Oct 09; 9(10):1273-82. PubMed ID: 27498886
    [Abstract] [Full Text] [Related]

  • 17. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
    Kolacek S.
    Acta Med Croatica; 2013 Apr 09; 67(2):89-92. PubMed ID: 24471292
    [Abstract] [Full Text] [Related]

  • 18. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M, Zacharias P, Ribeiro DA, Boaron L, Steckert Filho A, Kotze PG.
    Arq Gastroenterol; 2017 Dec 09; 54(4):328-332. PubMed ID: 28954043
    [Abstract] [Full Text] [Related]

  • 19. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W, Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Drugs Aging; 2020 May 09; 37(5):383-392. PubMed ID: 32016824
    [Abstract] [Full Text] [Related]

  • 20. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP.
    Am J Gastroenterol; 2017 Jan 09; 112(1):120-131. PubMed ID: 27958281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.